GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Diabetes · 2014
Last updated 2026-05-28In mice, a single dose of the GLP-1 drug liraglutide increased heat production in brown fat and converted white fat to a more active form, without changing food intake. This effect was blocked when a specific brain pathway in the hypothalamus was activated. In a 1-year study of 16 obese people with type 2 diabetes, two GLP-1 drugs (exenatide and liraglutide) raised energy expenditure, suggesting these drugs may help regulate body weight by affecting energy use as well as appetite.
AI summary of the abstract below.
| Journal | Diabetes, 2014 |
|---|---|
| Citations | 499 |
| Relative citation ratio | 16.62 |
| NIH percentile | 99 |
| Molecules | — |
| Conditions studied | Obesity, Cardiovascular Risk Reduction |
Abstract
GLP-1 receptor (GLP-1R) is widely located throughout the brain, but the precise molecular mechanisms mediating the actions of GLP-1 and its long-acting analogs on adipose tissue as well as the brain areas responsible for these interactions remain largely unknown. We found that central injection of a clinically used GLP-1R agonist, liraglutide, in mice stimulates brown adipose tissue (BAT) thermogenesis and adipocyte browning independent of nutrient intake. The mechanism controlling these actions is located in the hypothalamic ventromedial nucleus (VMH), and the activation of AMPK in this area is sufficient to blunt both central liraglutide-induced thermogenesis and adipocyte browning. The decreased body weight caused by the central injection of liraglutide in other hypothalamic sites was sufficiently explained by the suppression of food intake. In a longitudinal study involving obese type 2 diabetic patients treated for 1 year with GLP-1R agonists, both exenatide and liraglutide increased energy expenditure. Although the results do not exclude the possibility that extrahypothalamic areas are also modulating the effects of GLP-1R agonists, the data indicate that long-acting GLP-1R agonists influence body weight by regulating either food intake or energy expenditure through various hypothalamic sites and that these mechanisms might be clinically relevant.
Verbatim abstract via PubMed 24917578 ↗